of 40 /40
Drugs affecting Blood

Drugs affecting Blood - Weeblydrmys.weebly.com/uploads/2/9/1/8/2918671/drugs_affecting_blood.pdflung causing pulmonary embolism (PE) DVT: Deep Vein Thrombosis •Deep vein thrombosis

  • Author
    others

  • View
    3

  • Download
    0

Embed Size (px)

Text of Drugs affecting Blood - Weeblydrmys.weebly.com/uploads/2/9/1/8/2918671/drugs_affecting_blood.pdflung...

  • Drugs affecting Blood

  • Blood Clotting

    • Blood clots are also called thrombi

    • Develop from abnormalities with:

    – Blood coagulation

    – Blood flow

    – Platelet adhesiveness

    – Vessel walls

  • Blood Clotting

    • Anticoagulants

    – Prevent clot formation by inhibiting clotting factors

    • Antiplatelets

    – Reduce risk of clot formation by inhibiting platelet aggregation

    • Fibrinolytics

    – Dissolve clots already formed

  • Clotting Cascade

  • Clotting Cascade

    • If any factor in the cascade is missing,

    blood will not clot (hemophilia)

  • Venous Thrombi

    • Usually form in areas of slow blood flow,

    surgical or vein injuries, large venous

    sinuses, or pockets formed by valves in

    deep veins

    • If the clot breaks off, it can travel to the

    lung causing pulmonary embolism (PE)

  • DVT: Deep Vein Thrombosis

    • Deep vein thrombosis above the knee is the

    most serious and may be fatal

  • Risk Factors for DVT

    • Age over 40

    • Bed rest over 4 days

    • Estrogen combined

    with nicotine

    • High dose estrogen

    therapy

    • Major illness

    • Obesity

    • Pregnancy

    • Previous DVT

    • Surgery

    • Trauma

    • Varicose veins

  • Laboratory Testing

    • Certain lab tests must be done on patients

    who are on anticoagulant therapy

  • Laboratory Testing

    • Partial thromboplastin time (PTT) –

    affected by heparin

    • Prothrombin Time (PT) – affected by

    warfarin

    • International Normalized Ration (INR)

    • Hematocrit

  • Anticoagulant Agents

    • argatroban

    • bivalirudin (Angiomax)

    • fondaparinux (Arixtra)

    • Heparin (protamine sulphate is antagonist)

    • lepirudin (Refludan)

    • warfarin (Coumadin) (Vit K ,phytonadione is antidot)

    Drug

    List

  • Anticoagulant Agents

    Low-Molecular-Weight Heparins:

    • dalteparin (Fragmin)

    • enoxaparin (Lovenox)

    • tinzaparin (Innohep)

    Drug

    List

  • heparin

    • Inhibits thrombin formation preventing clots

    from forming

    • Only anticoagulant that does not cross the

    placenta

    • Given for prophylaxis of DVT in

    postoperative, bedridden, obese patients,

    and others

  • warfarin (Coumadin)

    • Prevents production of vitamin

    K-dependent clotting factors

    • Prevents future clots with no effect on

    existing clots

    • Should not be taken with ASA or NSAIDs

  • Figure 20.14 Heparin- and low-molecular-weight heparin

    (LMWH)–mediated inactivation of thrombin or

    Factor Xa

  • Antiplatelet Agents

    • aspirin

    • clopidogrel (Plavix)

    • ticlopidine (Ticlid)

    Drug

    List

  • Figure 20.4 Activation and

    aggregation of platelets. GP

    = glycoprotein.

    Figure 20.5 Aspirin irreversibly

    inhibits platelet cyclooxygenase-

    1.

  • Figure 20.6 Acetylation of

    cyclooxygenase-1 by aspirin.

    Figure 20.7 Mechanism of action

    of ticlopidine and clopidogrel. GP

    = glycoprotein

  • clopidogrel (Plavix)

    • Blocks ADP (adenosine diphosphate)

    receptors and prevents platelet adhesion and

    aggregation

    • Used to prevent MI and stroke

    • Major side effect is bleeding

  • Antiplatelet Agents

    Glycoprotein Antagonists:

    • abciximab (ReoPro)

    • eptifibatide (Integrilin)

    • tirofiban (Aggrastat)

    Drug

    List

  • Figure 20.8 Mechanism of

    action of glycoprotein (GP)

    IIb/IIIa–receptor blockers.

    Figure 20.10 Formation of fibrin

    clot.

  • Fibrinolytic Agents

    • alteplase (Activase)

    • reteplase (Retavase)

    • streptokinase (Streptase)

    • tenecteplase (TNKase)

    • urokinase (Abbokinase)

    Drug

    List

  • Figure 20.21 Activation of plasminogen by fibrinolytic agents.

  • Stroke

    • The brain is the most oxygen-rich organ

    • If cerebral circulation is stopped, the brain

    runs out of oxygen within 10 seconds, tissue

    dies and does not regenerate

    • A stroke is an interruption of oxygen supply

  • Types of Strokes

    • Ischemic Stroke

    • Cerebral Hemorrhage

  • Types of Strokes

    • Ischemic Stroke

    – Results from obstruction of blood flow due to a

    thrombus or emboli lodging in the blood vessel

    • Cerebral Hemorrhage

  • Types of Strokes

    • Ischemic Stroke

    • Cerebral Hemorrhage

    – Involves primary rupture of a blood vessel

    – Signs: sudden severe headache, stiff neck,

    stupor, or a combination of these

    – Effects are long-lasting and irreversible

  • Stroke Risk Factors

    • Modifiable:

    – Cigarette smoking

    – Coronary artery

    disease

    – Diabetes

    – Excessive alcohol

    intake

    – Hyperlipidemia

    – Hypertension

    – Obesity

    – Physical inactivity

  • Stroke Risk Factors

    • Non Modifiable

    – Age

    – Gender

    – Genetic predisposition

    – Prior stroke

    – Race

  • Stroke Management

    • Emphasis is on prevention

    – Antiplatelet therapy

  • Stroke Management

    • Emphasis is on prevention

    – Antiplatelet therapy

    – Anticoagulant therapy

  • Stroke Management

    • Emphasis is on prevention

    – Antiplatelet therapy

    – Anticoagulant therapy

    – Fibrinolytic intervention

  • Stroke Management

    • Emphasis is on prevention

    – Antiplatelet therapy

    – Anticoagulant therapy

    – Fibrinolytic intervention

    – Cerebrovascular surgery

  • Stroke Management

    • Emphasis is on prevention

    – Antiplatelet therapy

    – Anticoagulant therapy

    – Fibrinolytic intervention

    – Cerebrovascular surgery

    – Nonpharmacologic therapy

  • Stroke Management

    • Emphasis is on prevention

    – Antiplatelet therapy

    – Anticoagulant therapy

    – Fibrinolytic intervention

    – Cerebrovascular surgery

    – Nonpharmacologic therapy

    – Poststroke management

  • Stroke Management

    • Emphasis is on prevention

    – Antiplatelet therapy

    – Anticoagulant therapy

    – Fibrinolytic intervention

    – Cerebrovascular surgery

    – Nonpharmacologic therapy

    – Poststroke management

    • It is imperative to know the cause of the stroke to

    determine treatment

  • Antiplatelet Agents

    • Prevent platelet activation and formation of

    platelet plug

    – Can interfere with platelet aggregation induced

    by ADP (adenosine diphosphate) or

    – Interfere with synthesis of thromboxane

  • Anticoagulant Agents

    • Interfere with the synthesis and activation

    of the blood’s coagulation factors

    • May prevent existing clots from expanding

    • Does not reduce existing clots

  • Fibrinolytic Agents

    • Dissolve existing emboli or thrombi

    • Indications:

    – DVT

    – Acute peripheral occlusion

    – Acute MI with embolization

    – PE

    – Coronary embolus

  • Agents for TIAs and

    Stroke Prevention

    • aspirin

    • aspirin-dipyridamole (Aggrenox)

    • clopidogrel (Plavix)

    • dipyridamole (Persantine)

    • pentoxifylline (Trental)

    • ticlopidine (Ticlid)

    Drug

    List